In AML, CD97 is part of a signature of primary leukemic stem cell, a low-frequency leukemic subpopulation that possess stem cell properties and that is supposed to facilitate the development of relapse [84,86]. This evidence concerns the gene ADGRE2 and acute myeloid leukemia.